(PharmaNewsWire.Com, April 27, 2017 ) According to Publisher, the Global Next Generation Cancer Diagnostics market is estimated at $2.95 billion in 2015 and is expected to grow at a CAGR of 32.6% to reach $20.93 billion by 2022. Growing incidence of oncology diseases is expected to boost the demand for next generation cancer diagnostic tests market. However, lack of sufficient reimbursement policies for novel technologies and stringent regulatory procedures are the major factors that can hamper the global next generation cancer diagnostics market growth over the forecast period. The largest segment of the global market for next generation cancer diagnostics is Blood-born cancers. Asia Pacific is likely to be one of the fastest growing regions of this sector and is anticipated to grow at a lucrative rate. A largely untouched market base which has exhibited technological advancements in healthcare research during the past decade is responsible for rapid growth in this region.
Regions Covered: - North America - US - Canada - Mexico - Europe - Germany - France - Italy - UK - Spain - Rest of Europe - Asia Pacific - Japan - China - India - Australia - New Zealand - Rest of Asia Pacific - Rest of the World - Middle East - Brazil - Argentina - South Africa - Egypt
What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
Company Profiling 11.1 Abbott Laboratories 11.2 Agilent Technologies Inc 11.3 GE Healthcare 11.4 Genomic Health Inc. 11.5 Hologic Inc. 11.6 Illumina Inc. 11.7 Johnson & Johnson 11.8 Myriad Genetics Inc. 11.9 Novartis AG 11.10 Opko Health Inc. 11.11 Perkin Elmer Inc. 11.12 Philips Electronics NV 11.13 Qiagen 11.14 Roche Holding AG 11.15 Thermo Fisher Scientific Inc.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: